Optimer Pharmaceuticals (OPTR) said late Friday that the U.S. Food and Drug Administration has approved its antibacterial drug Dificid to treat clostridium difficile-associated diarrhea in adults.
Clostridium difficile-associated diarrhea, or CDAD, is a problem in hospitals and long-term care facilities, and is beginning to emerge in the community among people who had been thought to be at low risk for the disease, Optimer said.
Phase 3 clinical trials showed the drug to be superior to vancomycin in sustained clinical response in treating the condition.
Optimer has an agreement to market the drug in the U.S. with Cubist Pharmaceuticals (CBST).
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?
⤹
Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.7%—Every Month—Forever.
You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.7%.